title: Efficacy of adalimumab in the treatment of moderate-to-severe psoriasis: A retrospective study of 100 patients in daily practice.
abstract: OBJECTIVE
  To assess the efficacy and safety of adalimumab in biologic naïve versus non-biologic naïve psoriasis patients.
  
  
  METHODS
  A retrospective multicenter study of patients with moderate-to-severe psoriasis treated uninterruptedly with adalimumab between 6 and 36 months.
  
  
  RESULTS
  A total of 100 patients (52 men, 48 women; mean age 45.5 years; 90% plaque-type psoriasis) were included. Previous treatments included biologics in 53 and non-biologic modalities in 47. The mean (SD) start Psoriasis Area and Severity Index (PASI) score was 15.9 (11.1) (range 2-55). The median follow-up was 18 months (interquartile range 10-24 months). Sixteen weeks after the start of treatment, 94% of the patients presented PASI 75 response, 76% PASI 90, and 39% were in complete remission (PASI 100). Similar findings were obtained in the groups of biologic naïve and non-biologic naive patients. At the final visit, around 37% in all groups were in complete remission. At the end of the study, 74 patients continued treatment with adalimumab (43 [91.5%] in the biologic naïve group and 31 [58.5%] in the non-biologic naïve group, p<0.001).
  
  
  CONCLUSIONS
  This study confirms the efficacy and safety of adalimumab for moderate-to-severe psoriasis without differences between biologic naïve and non-naïve patients.
authors.affiliation: Service of Dermatology, Hospital Universitario Marqués de Valdecilla, Universidad de Cantabria , Santander , Spain .
authors.forename: Susana
authors.initials: S
authors.lastname: Armesto
authors.forename: Pablo
authors.initials: P
authors.lastname: Coto-Segura
authors.forename: Jesús
authors.initials: J
authors.lastname: Mayorga
authors.forename: Aitziber
authors.initials: A
authors.lastname: Illaro
authors.forename: Jorge
authors.initials: J
authors.lastname: Santos-Juanes
mesh_terms: D000068879:Adalimumab; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy* / Q000473:pathology; D012074:Remission Induction; D012189:Retrospective Studies; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D061067:Antibodies, Monoclonal, Humanized; D000068879:Adalimumab
keywords: Adalimumab; PASI score; anti-TNFα therapy; biologic agents; psoriasis; retrospective study